Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 263

1.

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM.

Infect Immun. 1994 Nov;62(11):5168-72.

PMID:
7927802
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

PMID:
8890204
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine.

Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY, Levine MM.

Infect Immun. 1996 Aug;64(8):3055-61.

PMID:
8757833
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

[Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].

Yang XF, Zhou L, Zheng J, Si LS, Wang YL.

Wei Sheng Wu Xue Bao. 2005 Oct;45(5):748-52. Chinese.

PMID:
16342769
[PubMed - indexed for MEDLINE]
6.

Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine.

Yoshikawa M, Sasakawa C, Okada N, Takasaka M, Nakayama M, Yoshikawa Y, Kohno A, Danbara H, Nariuchi H, Shimada H, et al.

Vaccine. 1995;13(15):1436-40.

PMID:
8578822
[PubMed - indexed for MEDLINE]
7.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
[PubMed - indexed for MEDLINE]
8.

AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys.

Kärnell A, Cam PD, Verma N, Lindberg AA.

Vaccine. 1993;11(8):830-6.

PMID:
8356844
[PubMed - indexed for MEDLINE]
9.

Virulence phenotype and genetic characteristics of the T32-ISTRATI Shigella flexneri 2a vaccine strain.

Venkatesan M, Fernandez-Prada C, Buysse JM, Formal SB, Hale TL.

Vaccine. 1991 May;9(5):358-63.

PMID:
1872021
[PubMed - indexed for MEDLINE]
10.
11.
12.

DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin.

Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR.

Vaccine. 2000 Apr 28;18(21):2193-202.

PMID:
10717338
[PubMed - indexed for MEDLINE]
13.

Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.

Koprowski H 2nd, Levine MM, Anderson RJ, Losonsky G, Pizza M, Barry EM.

Infect Immun. 2000 Sep;68(9):4884-92.

PMID:
10948101
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. I. Construction of vaccine candidate strains with retained invasiveness but reduced intracellular multiplication.

Linde K, Dentchev V, Bondarenko V, Marinova S, Randhagen B, Bratoyeva M, Tsvetanov Y, Romanova Y.

Vaccine. 1990 Feb;8(1):25-9.

PMID:
2180230
[PubMed - indexed for MEDLINE]
15.

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.

J Infect Dis. 2004 Nov 15;190(10):1745-54. Epub 2004 Oct 19. Erratum in: J Infect Dis. 2005 Jun 15;191(12):2161.

PMID:
15499528
[PubMed - indexed for MEDLINE]
Free Article
16.

Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.

Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, Venkatesan MM.

Vaccine. 2012 Jul 20;30(34):5159-71. doi: 10.1016/j.vaccine.2012.05.003. Epub 2012 May 30.

PMID:
22658966
[PubMed - indexed for MEDLINE]
17.

Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli.

Ranallo RT, Fonseka CP, Cassels F, Srinivasan J, Venkatesan MM.

Infect Immun. 2005 Jan;73(1):258-67.

PMID:
15618162
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri.

Levine MM, Woodward WE, Formal SB, Gemski P Jr, DuPont HL, Hornick RB, Snyder MJ.

J Infect Dis. 1977 Oct;136(4):577-82.

PMID:
333041
[PubMed - indexed for MEDLINE]
19.

Development of an auxotrophic oral live Shigella flexneri vaccine.

Lindberg AA, Kärnell A, Stocker BA, Katakura S, Sweiha H, Reinholt FP.

Vaccine. 1988 Apr;6(2):146-50. Review.

PMID:
2838986
[PubMed - indexed for MEDLINE]
20.

Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.

Formal SB, Hale TL, Kapfer C, Cogan JP, Snoy PJ, Chung R, Wingfield ME, Elisberg BL, Baron LS.

Infect Immun. 1984 Nov;46(2):465-9.

PMID:
6389344
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk